- Lonza extends collaboration with a major pharmaceutical partner for ADC commercial supply, building a new bioconjugation suite in Visp (CH), operational by 2027, creating 100 jobs.
Tue Oct 22 06:02:07 -0000 2024 UTC– Lonza extends collaboration with a pharmaceutical partner for commercial supply of Antibody-Drug Conjugates (ADCs), building new bioconjugation capacity in Switzerland, and providing commercial antibody supply for a new ADC therapy.
Lonza’s Critical Role in Cancer Treatment
Lonza is reinforcing its commitment to advancing cancer treatment by expanding its collaboration with a pharmaceutical partner. The extended agreement focuses on producing ADCs, which are used in innovative cancer therapies. These drugs combine antibodies and drugs to specifically target cancer cells while minimizing damage to healthy tissues.
Expanding Capacity in Switzerland
As part of this collaboration, Lonza is building a new bioconjugation facility in Switzerland. This site will bolster the company’s ability to meet growing demand for ADC therapies, as well as support the commercial supply of monoclonal antibodies (mAbs), a key component in many cancer treatments.
Supporting a Critical Industry
The collaboration not only strengthens Lonza’s position in the ADC field but also highlights its capability in developing, manufacturing, and scaling up advanced therapies. By combining their expertise in bioconjugation and mAb production, both companies are poised to make significant advancements in cancer care, offering new hope to patients worldwide.
About Lisa
Subscribe to Lisa’s Newsletter today!
Keep Up: Nobot.News Launches Breaking Newsletter